Work packages
Work package details
Coordinates consortium management, timelines, quality assurance and governance across all partners.
Achieve earlier detection of clinical deterioration and risk factors in hospital and home settings to prevent disease progression and complications. WP2 leverages digital health solutions, including non-contact monitoring, wearables, and remote management, empowering healthcare providers and patients to intervene early in the CVD continuum. The goal is to reduce avoidable ICU admissions, hospital readmissions, and undiagnosed recurrent ischemic events, offering patients an early exit from high-risk situations.
Tasks
- Task 2.1 – Camera-based in-hospital monitoring (CARDIO-CAM study)
- Task 2.2 – Nurse/HCP-led remote HF monitoring (REMODEL-HF study)
- Task 2.3 – Wearable BP monitoring and citizen science (EMPOWER-BP study)
- Task 2.4 – Enhanced wearable ECG/BP/PPG analysis
- Task 2.5 – Wearable post-ACS monitoring (Pathway-CV study)
- Task 2.6 – Patient-initiated ECG monitoring (HEART-CHECK study)
- Task 2.7 – Preventive analytics and AI integration
- Task 2.8 – Validation and refinement using existing large-scale cohorts
- Task 2.9 – Spectral CT for early detection, risk stratification and personalized patient care pathways (LEADER-PAD)
- Task 2.10 – Continuous monitoring of postpartum blood pressure for assessment and shifting of cardiovascular risk (COMPASS study)
- Task 2.11 – Dynamic ECG analysis and modeling for HF diagnosis, staging, and therapy optimization
- Task 2.12 – Patient-reported MI symptom awareness (PROMISE)
- Task 2.13 – Comparative validation of GE PCCT for enhanced coronary plaque characterization and clinical decision-making in high-risk patients (CSPC-CT)
Elevate cardiovascular risk stratification and therapeutic decision-making through advanced imaging and diagnostics. WP3 targets an intermediate exit from cardiovascular disease progression by employing cutting-edge imaging (particularly photon-counting CT, PCCT) and AI-supported analytics to guide clinical interventions, personalize treatment strategies, and detect subclinical disease. This WP evaluates new technologies in clinical settings and introduces a paradigm of imaging-directed therapeutic interventions.
Tasks
- Task 3.1 – Siemens PCCT imaging for atherosclerosis and Lp(a) therapy (REGRESS-PCCT-Lp(a) study)
- Task 3.2 – Imaging-guided PCI randomized trial (GUIDANCE-PCCT study)
- Task 3.3 – OPTIMA-CT study – Siemens PCCT vs. EID-CT for plaque characterization and management
- Task 3.4 – Siemens PCCT cohort sub-study – predictors of plaque progression/regression
- Task 3.5 – Advanced prediction of disease progression (PREDICT-CCTA study)
- Task 3.6 – Robotic echo probe validation (REDUCE-TTE study)
- Task 3.7 – Integration and clinical guidance tools
- Task 3.8 – Cohort-based validation of imaging biomarkers
- Task 3.9 – Advanced imaging in infiltrative cardiomyopathies (amyloidosis, Fabry disease, NOTIFY-2)
- Task 3.10 – Wearable AI prediction of peri-procedural myocardial infarction (FINGERPRINT-CAD)
Develop and evaluate innovative therapeutic strategies for patients in advanced stages of cardiovascular disease (CVD), offering a late-stage exit by restoring cardiac function or enabling recovery when conventional treatments have been exhausted. WP4 combines regenerative medicine, mechanical circulatory support, minimally invasive surgery, and ex vivo heart perfusion to address end-stage heart failure and complex coronary artery disease. The primary goal is to improve survival, enhance functional recovery, and increase quality of life for patients who would otherwise rely on long-term assist devices, transplantation, or face high mortality.
Tasks
- Task 4.1 – Regenerative therapy with EHM patches (CERTAIN-7T-X study)
- Task 4.2 – Temporary mechanical circulatory support (MCS) for myocardial recovery (BRIDGE-HF study)
- Task 4.3 – Impella-supported robotically assisted minimally invasive direct coronary artery bypass (IMPACT-MIDCAB study)
- Task 4.4 – Early escalation to Impella 5.5 in cardiogenic shock (RISE study)
- Task 4.5 – Optimizing HOPE perfusion for transplantation (HOPE perfusion study)
- Task 4.6 – Therapy optimization and clinical guidelines development
Integrates clinical data from WPs 2–4 into a secure analytics platform for cross-validation and AI-driven insights.
Assesses cost-effectiveness and maps regulatory pathways so innovations can reach routine clinical practice.
Evaluates whether interventions are feasible, sustainable and equitable for large-scale implementation.
Integrates sex, gender, ethnicity and socioeconomic fairness into predictive tools, trial design and outcomes.
Disseminates results, communicates with stakeholders and supports exploitation of EXIT-CVD outputs.
Ensures the project meets all ethics requirements.
More related content
Discover who drives the project and how work is organised across the consortium.